Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Cue Biopharma, Inc. CUE

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$27.5M
▲ 195.7% YoY
$-26.6M
$-21.9M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

We are a clinical-stage biopharmaceutical company developing a novel class of injectable therapeutics engineered to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases. Unlike conventional approaches that broadly activate the immune system, our Immuno-STAT® platform is designed to selectively modulate disease-relevant T cells, enhancing efficacy while minimizing off-target effects. We aim to leverage our differentiated platform to establish new standards of care, forge strategic partnerships, and accelerate clinical development. We were incorporated under the laws of the State of Delaware on December 31, 2014 under the name Imagen Biopharma, Inc. We changed our name to Cue Biopharma, Inc. in October 2016. As of December 31, 2025, we had 29 full time employees. Substantially all of our employees are located in Massachusetts.

Written from the business description in Cue Biopharma, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 16 March 2026. Every sentence was checked against that document before publication.

Growth

USD 27.5M
Revenue, FY2025 · full 9-year series below
Revenue $M Net income $M
FY2025 · Revenue 27.5 · Net income -26.6
10M20M-20M-40M
2017202020232025
Compound annual growth
+180.5%
+54.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +54.2% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−97 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -96.7% · Net -96.9%
-2000%-4000%
201720212025
ROE
FY2025 · ROE -121.1%
-50%-100%
201720212025
Three returns, three denominators.

Each USD of equity lost 121 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -21.9
-15M-30M
201720212025
Net buybacks $M Dividends $M
FY2023 · Dividends · · Net buybacks 0.0
-20M-40M
20192020202120222023

Total assetsUSD 42.2M
EquityUSD 26.4M
CashUSD 27.1M
Current ratio2.74×

Equity funds 63% of total assets.

The 9-year record

9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
CUE, 9-year financial record
Metric 202520242023202220212020201920182017
Revenue $B0.00.00.00.00.00.00.00.0◌
Operating income $B−0.0−0.0−0.1−0.1−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.1−0.1−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.0◌0.00.00.00.00.0◌
Net income $B−0.0−0.0−0.1−0.1−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.28−0.72−1.11−1.49−1.41−1.56−1.66−1.94−2.16
Dividend / sh $◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————
ROE %−121.1−149.0−98.7−80.8−61.2−67.1−82.9−81.6−37.7
Shares out B0.100.060.050.050.030.030.030.020.02

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 36 reconciliationsAUDITED

Reconciled in 9 of the 9 fiscal years we could check. 20 checks were skipped: the balance sheet is not tagged before 2017. 10 checks were skipped: EPS is not tagged before 2017.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2017

Share this section

Download image